iwCLL Program

Function Location
All YIM and iwCLL Meals and Breaks
EICC – The Exchange, 150 Morrison St, Edinburgh EH3 8EE, UK
Cromdale Hall, Level -2
Young Investigator Meeting
EICC – EICC – The Exchange, 150 Morrison St, Edinburgh EH3 8EE, UK
Pentland, Level 3
iwCLL Meeting
EICC – EICC – The Exchange, 150 Morrison St, Edinburgh EH3 8EE, UK
Pentland, Level 3
iwCLL Welcome Reception
The Edinburgh Castle
Castlehill, Edinburgh EH1 2NG, UK

* Oral Presentation

** Poster Presentation

Friday, 20 September
7:30 – 16:30
Young Investigator Meeting
19:30 – 21:30 iwCLL Welcome Reception at the
Edinburgh Castle
Saturday, 21 September
7:15 Breakfast Coffee & Tea
08:15 Welcome and Introductions
Opening Remarks
Peter Hillmen
08:30 History of CLL
Gerald Marti
THEME 1: BIOLOGY AND PATHOPHYSIOLOGY
Session 1:
The CLL (Epi)genome
08:45 Overview of the CLL Genome
Jonathan Strefford
09:05 The Epigenetic Features of CLL:
DNA Methylation
Christoph Plass
09:25
Insights From Tertiary Structure, Chromatin
Modifications, and Nuclear Organization
José Ignacio Martín-Subero
09:45
*Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification (2086)
Kate Ridout
09:55
*BIRC3 loss accelerates leukemic progression through activation of the non-canonical NF-kB signaling of del(11q) CLL cells (2133)
Miguel Quijada-Álamo
10:05
**Leukemia specific delivery of miR29b induces epigenetic reprogramming with cell cycle arrest and therapeutic benefit in Chronic Lymphocytic Leukemia (2188)
Natarajan Muthusamy
10:10
**Cooperation between SF3B1 mutation and ATM deletion in the development of CLL (2194)
Lili Wang
10:15 Morning Break
Session 2:
The CLL (Epi)genome (cont.)
10:45 Keynote
Evolution and Mathematical Modelling of
Cancer Genomes
Gad Getz
11:15 Functional Implications of Genomic Lesions
Catherine Wu
11:35
The Impact of Regulatory RNA Molecules
Marek Mráz
11:55 ATM: Pathway, Lesions, and Targeting
Tatjana Stankovic
12:15 *Effect of second-generation BTK inhibitors on the functionality of macrophages and neutrophils from CLL patients. (2088)
Mercedes Borge
12:25 *Pyroptosis as a drugable cell death pathway in Chronic Lymphocytic Leukemia: The other side of inflammation. (2052)
Angimar Uriepero
12:35 **Clinical impact of clonal and subclonal TP53 mutations and deletions in chronic lymphocytic leukemia: an Italian multicenter experience (2130)
Riccardo Bomben
12:40 **Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact (2136)
Jitka Malcikova
12:45
Lunch
Session 3: The B-Cell Receptor
13:45 Role of the B-Cell Receptor in B-Cell
Oncogenesis
Stefano Casola
14:15
Dissecting CLL Immunogenetics and
Emerging B-Cell Receptor Stereotypes
Kostas Stamatopoulos
14:35 CLL-Specific Aspects of B-Cell Receptor
Signaling
Graham Packham
14:55 *Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL. (1904)
Adam Linley
15:05 *Functional interplay between the B-cell receptor and NOTCH1 in Chronic Lymphocytic Leukemia and in Richter’s syndrome (2065)
Francesca Arruga
15:15 **Targeting MDSCs in CLL-bearing mice by suppressing the synthesis of secretory IgM via activation of RIDD (1987)
Chih-Chi Hu
15:20 **Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia (2047)
Pablo Morande
15:25 **Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome (2062)
Yucai Wang
15:30
Afternoon Break
Session 4: Microenvironment and Models of CLL
15:55 Linking the Microenvironment With CLL
Models
Nicholas Chiorazzi
16:15
In Vitro Modelling of the CLL
Microenvironment
Alan Ramsay
16:35 Murine and Xenograft Models of CLL
Shih-Shih Chen
16:55 Role of NOTCH1 in CLL and in Richter’s Transformation
Silvia Deaglio
17:15 *Mechanisms of Ibrutinib resistance in the Eµ-TCL-1 mouse model of chronic lymphocytic leukemia (2124)
Martina Seiffert
17:25 *3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib (1931)
Cristina Scielzo
17:35 **Analyzing the mutational landscape of two CLL mouse models overexpressing AID identifies proliferative fraction-associated tumor genes involved in leukemic development and progression (2049)
Pablo Morande
17:40 **Modelling Chronic Lymphocytic Leukemia microenvironment in vitro by exploiting newly-established 3D systems (2006)
Francesca Vittoria Sbrana
17:45 **Chronic lymphocytic leukemia remodels the fibroblastic reticular network that contributes to immunosuppression in the tumor microenvironment (2166)
Natalia Couto-Francisco
17:50 **IL10-producing CD38hi B-regulatory cells drive the immunosuppressive microenvironment in CLL and can be targeted with anti-CD38 immunotherapy (2193)
Alak Manna
17:55 End of day 1
Sunday, 22 September
07:00-8:00 Leveraging Next-Generation BTK Inhibitors in B-Cell Malignancies: Data Updates and Case Challenge
Industry Supported Symposium provided by MedScape, LLC and supported by an educational grant from AstraZeneca
7:15 Breakfast Coffee & Tea
THEME 2: INNOVATIONS IN THE ASSESSMENT OF CLL
Session 5: Innovations in the Assessment of CLL
08:15 Laboratory Assessment of CLL, Including MRD
as an End Point
Andrew Rawstron
08:35 Molecular Characterization of CLL
Richard Rosenquist Brandell
08:55 Clinical Assessment of CLL
Carol Moreno
09:15 Critical Assessment and New Development of
Prognostic Scoring Systems
Barbara Eichhorst
09:35 *Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL (1925)
Kevin Coombes
09:45 *Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. (1938)
Petra Langerbeins
09:55 **Undetectable Minimal Residual Disease Should be the Goal of Venetoclax Therapy in Relapsed and Refractory Chronic Lymphocytic Leukaemia (2089)
Thomas Lew
10:00 **Predicting tumor lysis syndrome in venetoclax-treated CLL patients (2008)
Anthony Mato
10:05 Morning Break
THEME 3: THERAPY
Session 6:
Initial Therapy
10:35 Early Intervention: Can We Justify It and What
End Points Should We Consider?
Petra Langerbeins
10:55 Current Initial Treatment of CLL – for Young
Patients
Florence Cymbalista
11:15 Current Initial Treatment of CLL – for Elderly
Patients
Valentin Goede
11:35 Treatment of CLL from 2019 Onwards: E1912 Trial
Tait Shanafelt
11:45 Treatment of CLL from 2019 Onwards: Alliance Trial
TBD
11:55 Treatment of CLL from 2019 Onwards: iLLUMINATE Trial
Alessandra Tedeschi
12:05 Treatment of CLL from 2019 Onwards: CLL14 Trial
Kirsten Fischer
12:15 *Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged ≥65 year of age: results with 5 years of follow-up for the RESONATE-2 study (1956)
Alessandra Tedeschi
12:25 *Obinutuzumab and ibrutinib treatment induction followed by a minimal residual disease-driven strategy in chronic lymphocytic leukaemia: long-term results in the ICLL-07 FILO trial (1962)
Alessandra Tedeschi
12:35 **Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood resulting in improved Progression-free survival: Results of UK NCRI Phase II/III GALACTIC trial (2121)
Talha Munir
12:40 **Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy (2017)
Anna-Maria Fink
12:45 Keynote
Overview of Clonal Evolution and Genomic Instability in CLL and Implications for Therapy
Daniel Landau
13:15 Lunch
Selecting the right strategy for the management of patients with treatment-naïve CLL
iwCLL symposium supported by Janssen Oncology
14:00 Introduction
Peter Hillmen
14:05 The Evolving Standard of Care for Treatment-Naïve Patients With CLL
Tait Shanafelt
14:25 Future Chemotherapy-Free Combinations
William Wierda
14:45 Integration of Biomarkers Into Treatment Decision-Making – More Important Than Ever?
Paolo Ghia
15:05 Roundtable Discussion Panel Discussion With Interactivity and Audience Q&A
15:25
Afternoon Break
Session 7:
Resistance Mechanisms
15:45 Development of Resistance to B-Cell Receptor
Inhibition
Jennifer Woyach
16:05 Development of Resistance to BCL2 Inhibition
Mary Ann Anderson
16:25 *Prevalence of BTK and PLCG2 mutations in chronic lymphocytic leukemia patients relapsing on ibrutinib: a European Research Initiative on CLL (ERIC) real-world study (2098)
Lydia Scarfo
16:35 *High surface tumor IgM levels associate with reduced response duration and with BTK bypass during ibrutinib therapy in CLL patients (2195)
Giorgia Chiodin
16:45 **CD8+ T-cell exhaustion induced by leukemic cells mediates progression in Chronic Lymphocytic Leukemia (CLL) (2096)
Isabel Jiménez
16:50
Binet/Rai Medal Presentation
17:05
Poster Session Reception
18:35
End of day 2
Monday, 23 September
07:00 – 08:00
Treatment of CLL and the value of testing for Minimal Residual Disease (MRD)
Industry Supported Symposium provided and supported by Adaptive Biotechnologies
7:15 Breakfast Coffee & Tea
Session 8:
Therapy of Relapsed/Refractory CLL
08:15 B-Cell Receptor-Inhibitor Therapy in Relapsed/
Refractory Disease
Susan O’Brien
08:35 BCL2-Inhibitor-Based Therapy and MRD in
Relapsed/Refractory Disease
John Seymour
08:55 Novel Combinations and MRD in Relapsed/
Refractory Disease
Matthew Davids
09:15 Defining Duration of Therapy: Is There a Role
for MRD?
Talha Munir
09:35 *Venetoclax combined with ibrutinib based on a minimal residual disease-guided approach in relapsed/refractory chronic lymphocytic leukemia: results of the IMPROVE study (2068)
Lydia Scarfo
09:45 *Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study (2143)
Talha Munir
09:55 **Biological responses to ibrutinib plus venetoclax in the Bloodwise TAP CLARITYstudy (2163)
Andrew Rawstron
10:00 **Pneumocystis jirovecii pneumonia and invasive fungal infection incidence and institutional prophylaxis practices in CLL patients treated with BTK inhibitors (1941)
Christine Ryan
10:05
Morning Break
Session 9:
Novel Strategies in Rel/Refr CLL
10:30 Evolution of Small Molecule Inhibitors:
New vs Old
John Byrd
10:50 Updates on Immune Therapy Strategies,
Including CAR T-Cell Therapy and Stem Cell
Transplant
Katy Rezvani
11:10 *ASCEND Phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2158)
Paolo Ghia
11:20 *T cell bispecific antibody combination immunotherapy for chronic lymphocytic leukemia (2063)
Despoina Papazoglou
11:30 **A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy (1943)
Danielle Brander
11:35 **Biology and targeting of mutant p53 in CLL (2172)
Janani Ravikrishnan
11:40 Debate: Future Management of CLL:
Is There a Role for Cellular Therapy?
Moderator: Anna Schuh
David Maloney (CAR T)
Johannes Schetelig (SCT)
Matt Davids (Novel-Novel)
12:20
Lunch
Session 10:
Real-World Data and Registries
13:00 CLL Clinical Genomics: Overview of the
National Programmes in Sweden, the US, the
UK, and France
Anna Schuh
13:20 Geographic Diversity and Management of CLL
in South American Patients
Carlos Sérgio Chiattone
13:40 Geographic Diversity and Management of CLL
in African Patients
Norah Akinola
14:00 Geographic Diversity and Management of CLL
in Indian Patients
Abraham Varghese
14:20 Geographic Diversity and Management of CLL
in Chinese Patients
Shenmiao Yang
14:30
Selected Abstracts
14:40
Afternoon Break
Session 11:
iwCLL UPDATES
Chair: Peter Hillmen
15:00 Current Efforts From European and US
Real-World Data
Christopher Fox (EU) and Anthony Mato (US)
15:30 An Update From the European Research
Initiative on CLL (ERIC)
Paolo Ghia
16:00
Reorganization of the iwCLL
Michael Hallek
16:30
Closing Comments
Peter Hillmen
16:45 Close of Workshop

– Agenda subject to change

* Oral Presentation

** Poster Presentation